Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment | Oncology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: July 21, 2021.

Published Online: August 11, 2021. doi:10.1001/jamaoncol.2021.4390

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Eliakim-Raz N et al. JAMA Oncology.

Corresponding Author: Salomon M. Stemmer, MD, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky St, Petah Tikva 49100 (salomon.stemmer@gmail.com).

Author Contributions: Dr S.M. Stemmer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Eliakim-Raz, Massarweh, and A. Stemmer contributed equally for this work.

Concept and design: Eliakim-Raz, Massarweh, S.M. Stemmer.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: A. Stemmer, S.M. Stemmer.

Obtained funding: Eliakim-Raz, S.M. Stemmer.

Administrative, technical, or material support: All authors.

Supervision: Eliakim-Raz, S.M. Stemmer.

Conflict of Interest Disclosures: Dr S.M. Stemmer received research grants (to the institution) from CAN-FITE, AstraZeneca, Bioline RX, BMS, Halozyme, Clovis Oncology, CTG Pharma, Exelixis, Geicam, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche, and owns stocks and options in CTG Pharma, DocBoxMD, Tyrnovo, VYPE, Cytora, and CAN-FITE. The remaining authors declare no conflicts of interest.

Additional Contributions: The authors thank the patients and their families and the nursing staff members at the Day Care Unit, Davidoff Cancer Center, Rabin Medical Center. The authors also thank the Rabin Medical Center Biobank and Dr Adva Levy-Barda for their support of this research. Lastly, the authors thank Avital Bareket-Samish, PhD, for medical editing support. She received financial compensation for her contribution.

References
1.
Massarweh  A , Eliakim-Raz  N , Stemmer  A ,  et al.  Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer.   JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2155Google Scholar
2.
Foundation  R . The R Project for Statistical Computing. Accessed June 27, 2021. http://www.r-project.org/
3.
Widge  AT , Rouphael  NG , Jackson  LA ,  et al; mRNA-1273 Study Group.  Durability of responses after SARS-CoV-2 mRNA-1273 vaccination.   N Engl J Med. 2021;384(1):80-82. doi:10.1056/NEJMc2032195PubMedGoogle ScholarCrossref
4.
Doria-Rose  N , Suthar  MS , Makowski  M ,  et al; mRNA-1273 Study Group.  Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19.   N Engl J Med. 2021;384(23):2259-2261. doi:10.1056/NEJMc2103916PubMedGoogle ScholarCrossref
5.
Harvey  RA , Rassen  JA , Kabelac  CA ,  et al.  Association of SARS-CoV-2 seropositive antibody test with risk of future infection.   JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close